Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$7.97 USD
-0.04 (-0.50%)
Updated Sep 17, 2025 04:00 PM ET
Pre-Market: $8.39 +0.42 (5.27%) 9:24 AM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Amicus Therapeutics, Inc. has a PEG ratio of 0.76 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.28.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FOLD 7.97 -0.04(-0.50%)
Will FOLD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FOLD
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for FOLD
FOLD forms 1,2,3 Pullback Bullish on September 17
This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Amicus (FOLD) Sees Favorable Upgrade Following Regulatory Developments
FOLD: Needham Upgrades Amicus Therapeutics to Buy with $14 Target | FOLD Stock News
Needham upgrades Amicus to Buy on reduced regulatory risk